Skip to main content

Articles

ACR 2017, Conference Correspondent

Long-Term Efficacy and Safety Results of SIRROUND-D Trial of Sirukumab in Patients with Active RA Despite DMARD Treatment

ACR 2017, Conference Correspondent

Upadacitinib (ABT-494) Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs

ACR 2017, Conference Correspondent

Sarilumab plus DMARDs Lower HbA1c in Diabetic and Nondiabetic Patients with Rheumatoid Arthritis

ACR 2017, Conference Correspondent

Highly Sensitive Cardiac Troponin I Levels in Peripheral Blood Predict CV Events in Patients with RA

Cost per Effectively Treated Patient with Sarilumab for Active, Moderate-to-Severe RA

Sarilumab Efficacy Maintained or Improved in Patients with RA Who Previously Received Sarilumab or Tocilizumab

Sustained Response in TARGET Study of Sarilumab + csDMARDs versus Placebo in RA Patients with Inadequate Response to TNF Inhibitors

Sarilumab + csDMARDs Effective Regardless of Baseline Disease Activity in RA Patients with Inadequate Response to TNF Inhibitors

Tocilizumab Monotherapy as Effective as TNF Inhibitors plus MTX in Patients with RA

ACR 2017, Conference Correspondent

An Updated Integrated Safety Analysis of Baricitinib for the Treatment of Moderate-to-Severe RA

Page 80 of 244
Results 791 - 800 of 2434